| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Academic Article
|
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
|
|
Academic Article
|
Metastatic bladder cancer: advances in treatment.
|
|
Academic Article
|
New chemotherapy regimens for advanced bladder cancer.
|
|
Academic Article
|
[New chemotherapy regimens for advanced bladder cancer].
|
|
Academic Article
|
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
|
|
Academic Article
|
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma.
|
|
Academic Article
|
Kidney cancer.
|
|
Academic Article
|
Treatment of metastatic urothelial cancer in the post-MVAC era.
|
|
Academic Article
|
Gemcitabine doublets in advanced urothelial cancer.
|
|
Academic Article
|
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
|
|
Academic Article
|
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
|
|
Academic Article
|
Docetaxel and exisulind in hormone-refractory prostate cancer.
|
|
Academic Article
|
Perioperative chemotherapy in locally advanced bladder cancer.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
|
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
|
Academic Article
|
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
|
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
|
Academic Article
|
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
|
|
Academic Article
|
Targeted agents for the treatment of advanced renal cell carcinoma.
|
|
Academic Article
|
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
|
|
Academic Article
|
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
|
Academic Article
|
New therapeutic options for renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
|
|
Academic Article
|
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
|
|
Academic Article
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
|
|
Academic Article
|
Bevacizumab and everolimus in renal cancer: a rational way forward.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
|
|
Academic Article
|
The cure of bladder cancer: the need for multidisciplinary efforts.
|
|
Academic Article
|
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
|
|
Academic Article
|
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
|
|
Academic Article
|
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
|
|
Academic Article
|
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
|
|
Academic Article
|
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
|
|
Academic Article
|
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
|
|
Academic Article
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
|
Academic Article
|
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
|
|
Academic Article
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
|
Academic Article
|
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
|
|
Academic Article
|
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
|
|
Academic Article
|
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
|
|
Academic Article
|
Maturing of renal cancer therapeutics.
|
|
Academic Article
|
Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
|
|
Academic Article
|
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
|
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
|
Academic Article
|
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
|
|
Academic Article
|
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
|
|
Academic Article
|
Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C.
|
|
Academic Article
|
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
|
|
Academic Article
|
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
|
|
Academic Article
|
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
|
|
Academic Article
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
|
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|